No Data
Fujilai: 2024 Annual Report
Fujilai: First quarter report 2025
Fujilai: 2024 Annual Report Summary
Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ) announced its 2024 annual performance, with a net income of 16.4061 million yuan, a decrease of 85.38%.
Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ) released its annual report for 2024, and the company's revenue is 0.429 billion yuan, ...
Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ): Currently, there are no related products for weight loss.
On February 21, Gelonghui reported that Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ) stated on the investor interaction platform that the company is currently not involved in any weight loss drug related products. In the field of anti-tumor, the company has made significant progress; Apatinib mesylate is a small molecule tyrosine kinase inhibitor that can inhibit tumor angiogenesis. Currently, the Active Pharmaceutical Ingredient of Apatinib mesylate has passed CDE approval, indicating that this Active Pharmaceutical Ingredient meets the pharmaceutical evaluation technical standards in China and has been approved for use in domestic market formulations, which will further enrich the company's product line and enhance its competitiveness.
Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ): The Active Pharmaceutical Ingredient Thioctic Acid has obtained CEP certification.
On February 13, Glonghui announced that Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ) received a Certificate of Suitability (CEP) for Active Pharmaceutical Ingredient lipoic acid issued by the European Directorate for Quality Medicines (EDQM). The original manufacturer of lipoic acid is STADA from Germany, which belongs to the class of Vitamins and is primarily used for diabetic polyneuropathy.
